Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
ABSTRACT Background Immunotherapy combined with chemotherapy has become the standard treatment for HER2‐negative gastric cancer (GC), but its clinical benefits remain limited, with a median progression‐free survival (mPFS) of 6–8 months and median overall survival (mOS) of 15–18 months. These outcom...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.71065 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|